An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

NCT01595009 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals